MASON, OH, December 11, 2012 – AssureRx Health, Inc. today announced four key additions to its leadership team. The management appointments coincide with the need to support increasing GeneSightRx pharmacogenomic testing services, which support healthcare providers in medication selection and the managing of side effects for patients with neuropsychiatric and other disorders.
“We continue to experience rapid adoption of our pharmacogenomic treatment support products that assist clinicians in selecting medications for patients with neuropsychiatric disorders. The additional management appointments enhance our capabilities in pharmacogenomic clinical trial development, new product development, pharmaceutical industry services, high throughput laboratory test operations, market development, and clinician education,” said James S. Burns, president and CEO of AssureRx Health. “Our goal is to build the leading personalized medicine company offering pharmacogenomic treatment decision support solutions for neuropsychiatric, pain, ADHD, and other disorders.”
Bryan M. Dechairo, PhD, Senior Vice President, Medical Affairs & Strategic Alliances, is responsible for clinical development of current and future products, as well as alliances with academic, pharmaceutical, and genomic partnerships. Bryan was previously head of Extramural Research and Development at Medco Research Institute, responsible for translating pharmacogenomics into medical and pharmacy practice innovations to improve Medco member health outcomes, as well as business development and strategic alliances impacting Medco’s research through to commercial products. Prior to joining Medco, Bryan led a multi-disciplinary team of scientists and clinicians to deliver novel biomarkers for drug development as Neuroscience Lead and Director of Molecular Medicine at Pfizer Global Research and Development. He also held drug target discovery or diagnostic development positions at Oxagen, Sequana Therapeutics, and Roche Molecular Systems. Bryan received a PhD in complex human genetics from the Institute of Childs Health at the University College of London.
Rao V. Mulpuri, PhD, MBA, Vice President, Laboratory Operations, is responsible for all AssureRx Health multi-site commercial laboratory testing. Rao previously served as Director, Scientific Operations at the Catholic Health Initiatives Center for Translational Research (CHIC), responsible for establishing operational, informatics, IT, quality and regulatory strategies, development and implementation of molecular diagnostic tests (LDTs), and IT systems for electronic health records and genomic data. At Beckman Coulter Genomics, Rao was responsible for managing a CLIA-certified, cGMP/GLP compliant molecular genomics, biobanking and biologics testing facility. His experience also includes operating management positions at Cogenics/Clinical Data, Icoria/Cogenics, and Paradigm Genetics/Icoria. Rao received a PhD in physiology and biochemistry from Vikram University and an MBA from the University of North Carolina.
Scott M. Roth, Vice President, Product Development, has been promoted to lead the AssureRx Health Product Development team in building and supporting AssureRx Health treatment decision product offerings and the AssureRx Health LIMS system. Scott has been responsible for leading development of both AssureRx Health platform software architecture and commercial product software. Scott has extensive prior experience in software product development covering military defense, airline ticketing, credit card, and other applications. Previously, Scott served as Software Development Manager at Domin-8 Enterprise Solutions, managing and leading a team of software developers building property management Microsoft Windows and web based applications. At Spotlight Solutions, Scott was responsible for design and development of the corporate portal and software products. At Attachmate Corporation, Scott was involved in developing some of the first commercially available e-commerce and e-banking web applications, and custom software applications for the United States Air Force and United Airlines.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.